Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment

Trial Profile

Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2018

At a glance

  • Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2018 Status changed from recruiting to completed, as reported in an abstract presented at the 41st Annual San Antonio Breast Cancer Symposium
    • 31 Aug 2018 Biomarkers information updated
    • 27 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top